Category Archives: Medicine Wellness Health

Medicine Wellness Health

The development of common diseases.

BlockHealth is the necessary game changer.

The development of common diseases.

Much has changed in recent decades about the way we live. Industrialization and the prosperity gained by our society have redefined our lifestyle. The omnipresence of processed foods and the decreasing need for exercise in everyday and professional life do not pass us by unnoticed.

Frequency of diseases increases sharply

This development becomes very clear from various diseases of civilisation such as obesity or diabetes. In hardly any country is the obesity rate still below 20%. Similarly, the development of diabetes now affects more than 420 million people. The global cost of diabetes is over $1.3 trillion.
The figures are not encouraging for children and young people either – quite the opposite. More than 124 million children worldwide are pathologically overweight, compared with only 11 million in 1975. It has long been proven that those who eat wrongly for years and decades and move little are at a significantly increased risk of suffering one or more of the numerous lifestyle-related diseases of civilization.

Prevention as a decisive key

The question is, how are already deficient health systems to meet these ever-increasing challenges in the future?
Instead of solving the problem at its root, diseases are still treated mainly in the form of symptom alleviation or suppression. The environment that is the main cause of diseases, such as one’s own lifestyle, and the inadequate accessibility of low-threshold health care and promotion are not recognized in our health system.

BlockHealth as a solution approach

BlockHealth is a paradigm shift towards self-determined health management.
Only with a change in awareness of one’s own health and the ability to promote and maintain one’s own health can the constantly increasing number of patients be contained in the long term.
At the same time, many processes along the supply chain must be made more efficient. As in about the doctor-patient contact, but also cooperation among health professionals. Doctors have an average of about 7 minutes per patient. In order to ensure the correct treatment, it must be possible to obtain a holistic picture of the patient within a very short time.

We are convinced that with BlockHealth we have laid the foundation for the implementation of exactly these goals:
– The efficient use and intelligent exploitation of your own health data
– Low-threshold opportunities to adopt a healthy lifestyle

More about the product and our solutions can be found at www.blockhealth.ai and on our BlockHealth Social Media Accounts.

BlockHealth – Dein persönliches Gesundheitsmanagement

BlockHealth ist dein Manager für deine persönlichen Gesundheitsdaten – und ein kompetenter Berater und Begleiter zu einer gesunden und nachhaltigen Lebensweise.

Wir haben es uns zur Aufgabe gemacht, eine Plattform zu schaffen, die dabei unterstützt, Probleme des heutigen Gesundheitssystems zu lösen – sei es die oft komplizierte Handhabung von Gesundheitsdaten und/oder der dazugehörigen Dokumente, Zeitmangel der Ärzte, fehlende Kontakt-, Beratungs- und Verknüpfungsstellen zwischen eigenen Gesundheitsthemen und den dazu benötigten Maßnahmen, oder die sportliche Betätigung, die oftmals zu kurz kommt: durch selbstlernende und auf den Nutzer individuell abgestimmte Tools steuert BlockHealth genau diesen Problemen entgegen und bringt das Potential auf, die eigene Gesundheit präventiv, nachhaltig und maßgeblich zu forcieren. Dabei ist uns Individualität, Nachhaltigkeit und die Anpassung auf den eigenen Lebensstil und Gesundheitszustand äußerst wichtig. BlockHealth kombiniert technisch sichere, einfach nutzbare Funktionen zur Verwaltung der eigenen Gesundheitsdaten mit künstlicher Intelligenz, um dir einen ganz persönlichen Weg zu selbstbestimmtem Gesundheitsmanagement zu ebnen.

Contact
BlockHealth GmbH
Fabian Aschauer
Peter-Behrens-Platz 2
4020 Linz
Phone: +43 660 34 26 887
E-Mail: office@blockhealth.ai
Url: https://www.blockhealth.ai

Medicine Wellness Health

healthbank 2.0 launched

healthbank has developed a new version of its health data platform – new functions make healthbank even better, safer and easier to use – new partners are integrated

healthbank 2.0 launched

healthbank Homepage

The health data platform healthbank continues to grow rapidly. The next milestone in this development is the launch of the new healthbank v2.0 healthcare platform. In a completely new architectural approach, security was raised to the highest level through end-to-end encryption and the range of functions for users was further expanded. The health platform is now optimally designed to integrate further partners and applications from the health sector quickly, efficiently and highly securely.

„With the introduction of healthbank 2.0 we ensure that our users‘ health data is kept absolutely safe and that users have full control over their health data,“ explains Schegg, CEO of healthbank. „In recent months we have developed a new version of our health data platform, which offers many new functions and is safer, better and easier to use for users.
healthbank 2.0 is based on a completely new security architecture with end-to-end encryption, adds Schegg. „This means that the health data is encrypted on the user’s personal device (PC, laptop or mobile phone) before it is transferred to healthbank’s cloud systems. This is a completely new way of safely storing health data and will bring about more trust and protection in the population.“
Upcoming projects
With the new software architecture and the implemented security mechanisms,
healthbank is now ready to connect further partners and applications with a healthbank account, says Schegg. The following projects are also in the pipeline:
-The two award-winning apps „CatchMyPain“ and „PainCompanion“ will soon be integrated into the healthbank. Users suffering from severe or chronic pain can benefit from the long-term pain documentation in the future and continue to share their experiences and thoughts. All generated pain data is securely stored in the healthbank account.
-healthbank works closely with the Swiss app developer „Rehaptix“. Rehaptix monitors the rehabilitation of patients with motor disabilities due to a neurological injury such as stroke, multiple sclerosis or Parkinson’s disease. All data generated in the app is securely stored in the healthbank and can also be passed on to other people.
-healthbank plans to integrate fitness trackers into the healthbank in the near future. With this service users can connect their fitness tracker with the healthbank. And if a user changes the tracker, this will no longer be a problem in the future – the data and the connection to the healthbank will remain intact.

„With the new version of healthbank, our users can securely share their data with recipients of their choice in the future – and, if they are interested, they can participate in research projects worldwide or make their health data available to research institutions,“ explains Schegg.

About healthbank
healthbank is the world’s first citizen-owned, neutral and independent health data transaction platform that enables people to share their data in a secure and privacy compliant way with other partners. healthbank connects data sources of all kinds from the entire health sector and rewards participants to share their health data for research purposes. Based in Switzerland, healthbank stands for Swiss neutrality, trust and data protection and enables participating citizens, researchers and organisations with large amounts of data to network with each other. Thus, the value of health and medical data can be optimally tapped on this independent, global health platform. healthbank promotes innovations in health care, from prevention to cure, at a more reasonable price and of better quality, for the benefit of individuals and society.
www.healthbank.coop

Press contact healthbank
healthbank innovation AG
Karsten Stampa CFO/COO
Blegistrasse 17a, CH-6340 Baar
Tel. +41 (0) 41 552 24 00
press@healthbank.coop

healthbank ist die weltweit erste bürgereigene, neutrale und unabhängige Gesundheitsdaten-Transaktionsplattform, die es Menschen ermöglicht ihre Daten auf sichere und datenschutzkonforme Art und Weise mit anderen Partnern zu teilen. healthbank verbindet Datenquellen aller Art aus dem gesamten Gesundheitsbereich und belohnt Teilnehmer, ihre Gesund-heitsdaten für Forschungszwecke zu teilen. Mit Sitz in der Schweiz steht healthbank für schweizerische Neutralität, Ver-trauen und Datenschutz und ermöglicht es den teilnehmenden Bürgern, Forschern und Organisationen mit großen Daten-mengen sich miteinander zu vernetzen. Damit kann der Wert von Gesundheits- und medizinischen Daten auf dieser unab-hängigen, globalen Gesundheitsplattform optimal erschlossen werden. healthbank fördert Innovationen im Gesundheits-wesen, von der Prävention bis zur Heilung, zu einem angemesseneren Preis und besserer Qualität – für das Wohl des Ein-zelnen und der Gesellschaft.
www.healthbank.coop

Company-Contact
healthbank
Pauline Geniets
Blegistrasse 17a
6340 Baar
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Press
healthbank
Roger Huber
Gartenstrasse 36
8002 Zürich
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Medicine Wellness Health

biolitec®: Risk patients benefit from laser channel technology for BPH

Laser channel technology with biolitec® lasers successfully applied to treat in high-risk patients in Japan – Gentle, safe, fast, few side effects – Excellent hemostasis with fast, residue-free ablation

biolitec®: Risk patients benefit from laser channel technology for BPH

Prostate treatment with biolitec® fiber TWISTER (Source: biolitec biomedical technology GmbH)

Jena, July 11th, 2018 – The minimally invasive laser treatment LIFE (Laser Induced Flow Enhancement) by medical laser pioneer biolitec biomedical technology GmbH with its channel technology is particularly well suited for the treatment of benign prostate hyperplasia in high-risk patients. This is due to the optimal wavelength of the biolitec® laser (980 nm and 1470 nm) and to the special properties of the TWISTER and XCAVATOR® laser fibers, also specially developed by biolitec®. These are currently one of the gentlest, safest and fastest laser treatments with the fewest side effects and are therefore particularly suitable for high-risk patients. The channel technology offers the possibility of removing the tissue of the urinary tract of the prostate from the inside in a targeted manner without leaving any residue.

The biolitec® laser was one of the first lasers on the market with a wavelength of 980 nm and 1470 nm. This wavelength offers the highest absorption in water and hemoglobin and consequently enables excellent hemostasis. Less bleeding during the procedure improves visibility in the surgical area.
The TWISTER and XCAVATOR® laser fibers stand out due to their enlarged contact area and a special coating on the fiber tip, which enables faster ablation and more precise fiber guidance. The biolitec® fibers also work in contact mode. This significantly reduces the coagulation zone (smaller than 1 mm) and the bladder and surrounding tissue are protected, incontinence and sexual dysfunction are usually avoided.

The LIFE method has proven itself among other things in the treatment of high-risk patients. Urologists at Harasanshin Hospital Fukuoka in Japan have helped to develop this special channel technique and have operated on 26 patients who either suffer from diabetes and/or need to take anticoagulants. In addition, all patients had large prostates (on average over 100 to 200 g).

Doctors at Harasanshin Hospital Fukuoka were able to operate much faster than with conventional procedures – one hour on average – and to reach a large cavity without having to remove the tissue completely. The side effects, such as swelling, dysuria or retention, which are particularly common in large glands, did not occur. In addition, the treating physicians were enthusiastic about the good manageability and quality of the biolitec® laser system.

Further information on biolitec® lasers and special fibers as well as the possibilities of participating in workshops for doctors can be found on the website www.biolitec.com. Interested patients can find out more about doctors who use the LIFE method at www.info-prostate.com.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Best Hair Transplant in Turkey; Clinics and Offers

Best Hair Transplant in Turkey; Clinics and Offers

Over the last few years Turkey has became the first destination when it comes to health tourism. The best hair transplant in turkey offers all what a patient can ask for ; from the post surgery follow-up to the final guaranteed result. Hair transplant and plastic surgery are a flourishing filed in Turkey; clinics and hospitals are competing each other to offer the best services packages and to fulfill the needs and demands of their international patients , which qualifies them to be; not only the best hair transplant clinic in turkey but also in the world . If you are wondering how to find the best hair implants in turkey and how to make the best choice and choose the right clinic or surgeon this article is going to answer to the latter questions.

Best hair clinic in turkey is a little bit hard to find ; as we can’t name one clinic or hospital and refer to it as the ultimate best choice . Going through several clinics‘ and surgeons‘ results old patients‘ feedback and price offers can be the determinant point to either make a step forward and engage with the clinic or move on and look for the best hair transplant center in turkey . Sometimes it can be surprising when it comes to the difference in prices between clinics and hospitals ; for the reason of services including with the surgery and the used technique . Best hair transplant in turkey istanbul depends on the reputation of the surgeon; his experience and patients‘ satisfaction.

Best hair transplant in turkey istanbul offers a variety of methods ; Nowadays, hair transplantation can be reduced to two main techniques: FUE and DHI. Which method is best for me and how many grafts do i need ; is one session enough to cover all my baldness ; are the most frequently asked questions before engaging to have the surgery done , most of the time in the process of searching for the best place for hair transplant in turkey on the internet or online medical platforms can not answer to all your questions and inquires and even sometimes it can be misleading. For this reason, the best way to get an accurate estimate of the cost and best technique for you would be to set up a consultation with a hair transplant specialist ; best hair transplant doctors in turkey who can evaluate your particular situation. It is difficult to generalize an average cost of hair transplant procedures as it depends on the specificity of each patient’s hair loss circumstances.

Eurozen Hair exist a great team including 44 persons ,13 asistan nurses,12 persons who are experts at plastic surgeon and 19 experts proffessional hair planters.
We realize your hairtransplantation by expert surgens and team proffessional.Eurozen Hair Transplant is the company which has a legal accountability and is rigorous about the hospital and health personnel.
We serve for 16 years with our equipmant which has latest technology, equipped operating rooms,academic staff and special doctors in enviroment of hospital full-fledged.
Eurozen has mission and vision providing Turkey as one of the first places in the world about hair tranplantation, sharing many contents of information and technical, following the developments in Canada,U.S.A, and Europe about hair transplantation.

Company-Contact
EuroZen Hair Transplant Center
Ismail Zengin
Fulya Life Residence Merkez Mah. Prof. Dr. Bülent Tercan Sok. No:16 16
34394 istanbul
Phone: +90(542) 231 2810
E-Mail: info@eurozenhairtransplant.com
Url: https://en.eurozenhairtransplant.com

Press
EuroZen Hair Transplant Center
ahmet taş
Fulya Life Residence Merkez Mah. Prof. Dr. Bülent Tercan Sok. No:16 16
34394 istanbul
Phone: +90(542) 231 2810
E-Mail: info@eurozenhairtransplant.com
Url: https://en.eurozenhairtransplant.com

Medicine Wellness Health

healthbank enters into partnership with Sanovation

Health database platform healthbank gains over 200,000 additional users with pain diary apps from Sanovation

healthbank enters into partnership with Sanovation

Sanovation

Merger of two Swiss start-ups in the digital health sector. With the cooperation of the health data platforms healthbank from Baar and Sanovation AG from Zug, the users of the two innovative start-ups will receive a multitude of new possibilities with their health data.

Sanovation brings over 200,000 registered users of its pain diary apps „CatchMyPain“ and „Pain-Companion“ into the partnership. healthbank in return
offers users a highly secure storage for health data under their full control and an innovative data exchange platform. As a central agency for individuals, health service providers and researchers, healthbank increases the quality of care and lowers global health costs.

„The partnership with Sanovation is a further step towards a successful future for healthbank,“ explains Reto Schegg, CEO of healthbank. „With this partnership, users of the award-winning ‚CatchMyPain‘ and ‚Pain Companion‘ apps will be absolutely certain that their health data is not only safe and in full control. Users can also share data with recipients of their choice – participate in research projects worldwide and make their data available to research institutions. You will even be rewarded.“

One in five adults suffers from chronic pain
Today, according to Sanovation, one in five adults suffers from chronic pain. The aim of the intelli-gent pain diary „CatchMyPain“ is to enable a detailed, ongoing recording of pain samples. With „Pain Companion“, users can find similar patients by comparing the pain diaries, who can exchange information directly with each other or in a community. Thanks to the two Sanovation Apps, patients and their doctors and therapists receive a meaningful communication tool, especially through long-term recording.

The analysis of a large number of pain diaries, if users allow it, will lead to new findings in pain medicine. Reto Schegg adds: „The knowledge about chronic pain is currently scattered on many paper archives of doctors, therapists and hospitals. This makes it practically impossible to systematically compare and analyze pain cases. The cooperation between Sanovation and healthbank can signifi-cantly improve this problem. For Sanovation CEO and Chairman of the Board Roman Haag, this could improve the quality of life of millions of patients worldwide. In addition, administrative processes and treatments become more efficient and thus more cost-effective. „The cooperation with healthbank will improve the situation of chronic pain patients in the long term. On the other hand, we see great potential in the integration of additional data sources such as medication or fitness data, which is only made possible by the cooperation with healthbank. Haag explains. With the new basic data protection regulation of the European Union (GDPR), the cooperation makes an important contribution to the data protection of users. According to Reto Schegg, „CatchMyPain“ and „Pain Companion“ are just two of many applications that will be running on the healthbank platform in the future and with which users can manage their health data, explains Reto Schegg.

About Sanovation AG
The pain diary CatchMyPain is developed and maintained by the Swiss start-up Sanovation AG in Zug. Sanovation was founded in November 2011 and since then works exclusively on CatchMyPain. The idea for CatchMyPain came from the pain story of a co-founder. The application is primarily aimed at people with chronic pain who feel similar pain over a longer period of time. The vision of Sanovation AG is to help individual users on the basis of all collected user data by com-paring symptoms and making recommendations.

About healthbank
healthbank is the world’s first citizen-owned, neutral and independent health data transaction platform that enables peo-ple to share their data in a secure and privacy compliant way with other partners. healthbank connects data sources of all kinds from the entire health sector and rewards participants to share their health data for research purposes. Based in Switzerland, healthbank stands for Swiss neutrality, trust and data protection and enables participating citizens, research-ers and organisations with large amounts of data to network with each other. Thus, the value of health and medical data can be optimally tapped on this independent, global health platform. healthbank promotes innovations in health care, from prevention to cure, at a more reasonable price and of better quality, for the benefit of individuals and society.
www.healthbank.coop

Press contact healthbank

healthbank innovation AG
Karsten Stampa CFO/COO
Blegistrasse 17a, CH-6340 Baar
Tel. +41 (0) 41 552 24 00
press@healthbank.coop

Press contact Sanovation

Sanovation AG
Weinbergstrasse 48, CH-6300 Zug
Roman Haag, VRP
contact@sanovation.com

healthbank ist die weltweit erste bürgereigene, neutrale und unabhängige Gesundheitsdaten-Transaktionsplattform, die es Menschen ermöglicht ihre Daten auf sichere und datenschutzkonforme Art und Weise mit anderen Partnern zu teilen. healthbank verbindet Datenquellen aller Art aus dem gesamten Gesundheitsbereich und belohnt Teilnehmer, ihre Gesund-heitsdaten für Forschungszwecke zu teilen. Mit Sitz in der Schweiz steht healthbank für schweizerische Neutralität, Ver-trauen und Datenschutz und ermöglicht es den teilnehmenden Bürgern, Forschern und Organisationen mit großen Daten-mengen sich miteinander zu vernetzen. Damit kann der Wert von Gesundheits- und medizinischen Daten auf dieser unab-hängigen, globalen Gesundheitsplattform optimal erschlossen werden. healthbank fördert Innovationen im Gesundheits-wesen, von der Prävention bis zur Heilung, zu einem angemesseneren Preis und besserer Qualität – für das Wohl des Ein-zelnen und der Gesellschaft.
www.healthbank.coop

Company-Contact
healthbank
Pauline Geniets
Blegistrasse 17a
6340 Baar
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Press
healthbank
Roger Huber
Gartenstrasse 36
8002 Zürich
Phone: +41 44 202 61 60
E-Mail: roger.huber@huber-media.ch
Url: http://www.healthbank.coop

Medicine Wellness Health

New study: Increased risk of thrombosis among patients with varicose veins – Laser therapy ELVeS® Radial® 2ring especially for varicose vein patients

Patients with varicose veins have four to five times higher risk of thrombosis – New study from Taiwan shows connection – Risk of pulmonary embolism also increased – ELVeS® Radial 2ring method by biolitec® particularly suitable

New study: Increased risk of thrombosis among patients with varicose veins - Laser therapy ELVeS® Radial® 2ring especially for varicose vein patients

ELVeS® Radial® 2ring fiber during the treatment (Source: @biolitec biomedical technology GmbH)

Jena, June 12, 2018 – Longer flight or car journeys, sedentary activities and sitting with bent legs for long periods have an impact on the blood flow. This is sometimes followed by swollen and aching legs. In unfavorable cases, this may even result in thrombosis: a blood clot or thrombus, which can cause pain and, in the worst case, pulmonary embolism. A visit to the doctor is inevitable in case of thrombosis. A connection with the occurrence of thrombosis has now also been discovered concerning varicose veins. Varicose veins are common, but rarely associated with serious health risks. However, a new study* published in February 2018 in Taiwan has shown that there is an association between the presence of varicose veins and the future development of deep vein thrombosis. The data basis for the study was compiled from a Taiwanese health insurance program. The aim was to examine the connection between varicose veins and increased risk of deep vein thrombosis, pulmonary embolism or peripheral artery disease. Over 200,000 patients diagnosed with varicose veins or treated for varicose veins have been examined during the study. The control group without varicose veins was the same size.

In the group of varicose vein patients, the risk of thrombosis was five times higher than in the group without varicose veins – regardless of sex and age. The study also revealed a 70% higher risk of pulmonary embolism. In the first year after diagnosis, the risk of thrombosis was particularly high, presumably because those affected seek medical help only in cases of severe suffering and have not yet received treatment.

It can be assumed that varicose veins are a sign of a damaged vascular system with an increased risk of inflammation and thrombosis. In the event that acute and chronic venous diseases are diagnosed, the patients should discuss the personal risk with their doctor.

If it turns out that the removal of varicose veins is medically advisable, the minimally invasive therapy with the ELVeS® Radial® 2ring method of biolitec® is also particularly suitable for high-risk patients. With the ELVeS® Radial® method, the surgeon removes the varicose veins with a very fine laser fiber. The specially developed two-phase ring-shaped radiation of the fiber closes the vein from the inside, protecting the surrounding healthy tissue. The treatment is carried out within a short time and usually without general anesthesia. In addition, it enables patients to resume their lifestyle habits quickly.

Patients can find further information on the gentle laser therapy by biolitec® on the website www.info-varicose-vein.com. Information on doctors who apply the ELVeS® Radial® method is available to patients via the e-mail address post@info-varicose-vein.com and by telephone via the biolitec® hotline +49 6172 27159-11.

*ChangSL et al. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. JAMA 2018; 319:807-17

A retrospective cohort study using data from the Taiwanese health insurance program. From January 01, 2001, to December 31, 2013, 212,984 varicose vein patients aged 20 years and older and a control group of the same number of patients without varicose veins have been included and compared. Patients previously diagnosed with deep vein thrombosis (DVT), pulmonary embolism (PE) or peripheral artery disease (PAD) were excluded. The follow-up ended on December 31, 2014.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Maisense Presents Smart AI Cardiovascular Care Solution

Maisense Presents Smart AI Cardiovascular Care Solution

Freescan, the personal cardiovascular monitoring device (Source: © Maisense)

First all-in-1 Personal Cardiovascular Monitor and AI-based Stroke Prevention System to enable early detection of key factors indicating stroke risk

Hsinchu, Taiwan May 28th, 2018 – Maisense, an innovative startup, devotes itself to stroke prevention. The company“s corporate mission is to assist users with early detection of atrial fibrillation, and to support physicians in the efficient treatment and better cardiovascular care for their patients. Unlike other cardiovascular care products, which need multiple devices to measure ECG/EKG and blood pressure separately, Maisense Freescan in combination with the myFreescan App delivers an all-in-1 solution for early atrial fibrillation detection, arrhythmia (bradycardia and tachycardia) detection, pulse wave velocity, and blood pressure monitoring in a single device.

The Maisense Healthy Heart Hub (HHH) is a smart solution for cardiovascular care which consists of 3 components:

1. Freescan – the personal cardiovascular monitoring device for the patients and health conscious users. The device senses the lead 1 ECG and radial artery pulse by using 3 electrodes (1 as RA, 1 as LA, 1 as RL) combined with 1 pressure sensor. With the aforementioned bio-signals, Freescan can register parameters such as pulse transmission time (PTT), and calculates systole (SYS) and diastole (DIA) blood pressure respectively according to a formula. The devices can also calculate the heart rate (HR) and indicates irregular heartbeat. With its build-in Bluetooth technology, Freescan uploads each measurement to the Mobile App, and combines it with Maisense artificial intelligence (AI) to provide additional conclusions. The device has received an EU CE medical certification.

2. myFreescan – the Mobile App for patients or health conscious users to keep track of their personal health trends and to screen AFib/Arrhythmia. In addition, the pulse waveform and ECG/EKG waveform captured by Freescan provide the artery pulse wave velocity which is the indicator for artery stiffness and alerts the user to seek professional medical advice.

3. The Patient Care System – the platform used by doctors and professional physicians to monitor a patient“s vital parameters. Through the system personalized advices can be given instantly to guide patients. A detailed health report can be generated by the doctors via the system to support the patients for short-term/long-term heart health monitoring.
Freescan could proof a highly exact performance compared with Holter monitor systems in clinical field tests. In May 2018, Maisense finished the clinical research on AFib detection in the Chang-Gung Memorial Hospital, Keelung, Taiwan. The clinical results demonstrate the feasibility of using Freescan in detecting AFib as the preliminary screening results with over 95% sensitivity and over 99% specificity. The clinical results are under submission to the American Heart Association (AHA) 2018.

Maisense will present the solution at the ESH (European Society of Hypertension) conference in Barcelona from June 8th-11th in hall 8, booth 22, In addition to product demos for Freescan, myFreescan and the Patient Care System, the Maisense experts are available to discuss atrial fibrillation detection and the latest results of clinical studies.

Freescan is now available in Germany at Mindtech ( https://www.mindtecstore.com/Maisense_1). Maisense is looking for distributors in European Union.

Maisense is proud to be a member of the Global Research & Industry Alliance (GLORIA-Semicon) which focuses on future-oriented technology and builds a cooperation platform between universities and the industry. The organization stimulates innovation and introduces Taiwan startup companies to the global market. GLORIA will also exhibit alongside Maisense at ESH – booth 22.

About Maisense:
Maisense is an innovative startup working in non-invasive medical cardiovascular monitoring for personal use, combined with artificial intelligence software for stroke prevention including AFib/arrhythmia/artery stiffness detection for professional physician use. Founded in 2012, Maisense was granted the award for „Best Investment Potential“ by Taiwan“s Ministry of Economic Affairs. Maisense“s Freescan is the world first cuffless blood pressure monitor measuring directly from wrist pulse and it has received EU CE medical certification. It has been honored with the 2015 National Innovation Award in Taiwan, as well as ranking second among the Top 10 Innovative Health Products at the Arab Health 2016 fair in Dubai. In 2017, it has received the „Taiwan top 10 coolest innovative startups award“ from the Ministry of Science and Tech in Taiwan. For more information, visit www.maisense.com

About GLORIA-Semicon:
„GLORIA-Semicon“ – (Global Research & Industry Alliance Semiconductor) of Taiwan Ministry of Science & Technology is a platform that promotes high value-added and cross-field innovative products and services, and also dedicates in exploring and expanding the opportunities for members“ pioneering design to connect with Taiwan industry and academy resources. For more information, please visit http://riact.nctu.edu.tw/

GLORIA-Semicon is now coordinating a special interest group (SIG) for biomedical devices providers. Connections in between medical doctors, clinical trials as well as interdisciplinary researches are being sponsored by Taiwan government. We welcome international partners and jointly explore new businesses and channels especially in Chinese communities.

Dedication of GLORIA-Semicon:
– Allying global entrepreneurs with Taiwan semiconductor eco-system
– Providing one-stop services
– Facilitating global entrepreneurs in Taiwan to connect with local resources
– Collaborating with excellent academic groups in technical development

Company-Contact
Pressoffice Maisense
Wibke Sonderkamp
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.40
E-Mail: wibke@gcpr.net
Url: http://www.maisense.com/en/

Press
Pressoffice Maisense
Laura Lehmann
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.52
E-Mail: laura@gcpr.net
Url: https://www.gcpr.de/

Medicine Wellness Health

www.biolitec.com: New website presents modern medical laser therapies

biolitec® has launched a new website – Functional modern design – Worldwide leading developer and manufacturer of minimally invasive laser therapies – Successful research and development in areas such as phlebology and proctology – 10 years ELVeS®

www.biolitec.com: New website presents modern medical laser therapies

biolitec®_Homepage_en (Source: @biolitec biomedical technology gmbh)

Jena, May 22, 2018 – The developer and manufacturer of medical laser systems for minimally-invasive therapies, biolitec biomedical technology GmbH, has unveiled its new online presence. A modern layout now stands for an adapted innovative website functionality and a better overview of the company’s versatile product and application areas: Thanks to the new tile design, the entire website is structured in a way that the extensive range of medical applications and laser systems of biolitec® can be recognized at first glance.

This principle of fast recognition can be found both in the subject area for doctors and for patients. This, for instance, gives doctors an immediate overview of all biolitec® lasers. For example, if the visitor clicks on the „Dual 100“ tile, he can, due to the simple depiction, see all the therapeutic areas in which this laser can be used.

The same applies to patients: The respective therapy subpages under the menu item „patients“ lead directly to the patient websites adapted to the special needs of patients, such as www.info-varicose-vein.com, which can also be accessed as independent websites.

Founded more than 30 years ago, biolitec® has become one of the world’s leading companies in the field of minimally invasive laser therapies – due to continuous research and development of its products. Thanks to subsidiaries, including in South America and Asia, its innovative laser systems and methods are available for a wide range of applications for gentle and low-intensity treatment options all around the globe. biolitec® lasers are often innovative alternatives to conventional treatment methods in phlebology, proctology, thoracic surgery, urology, gynecology, ENT and orthopedics.

For 10 years now, the unique ELVeS® Radial® 2-ring laser fiber of biolitec®, with its efficient and simple technology, has been convincing in the treatment of varicose veins.

As a result of intensive research, biolitec® has always been able to offer the most modern possibilities in minimally invasive laser medicine. The new LEONARDO® laser family by biolitec® includes the only laser systems available on the market in which two wavelengths can be adjusted and used independently and continuously during the treatment. The universal applicability of the lasers in various fields of application is unique.

Further information on all products and applications of the laser therapies by biolitec® is available directly on the new website www.biolitec.com.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

First patient treated in First-in-Man study of CoreMedic“s ChordArt™ mitral valve repair system

16 May 2018. Privately-held CoreMedic announces the start of a first-in-man „Chagall“ study to evaluate new minimally-invasive valve repair technology.

CoreMedic is developing ChordArt, a novel transfemoral chordal repair system to address unmet needs in the treatment of degenerative heart disease with mitral valve insufficiency, the most common valve pathology affecting more than 7 million patients worldwide. The ChordArt implant is used to replace the ruptured or elongated chordae of the valve and re-establishes the connection of the valve leaflets with the papillary muscle to restore the proper function. As ChordArt reduces the complexity of the procedure, both patients and physicians will benefit.

The „Chagall“ Trial is a prospective, multicenter, first-in-man study intended to establish the safety and effectiveness of the ChordArt System. The study was approved to enroll up to 40 subjects at up to 6 European centers. This study is the first trial of its kind to treat patients that have ruptured or elongated mi-tral chords with the ChordArt System.

The first-in-man (FIM) case using ChordArt was treated by the Heart Team led by Prof. Kstutis Ručinskas at the Vilnius Uni-versity Hospital, Lithuania. The ChordArt treatment was aimed at improving procedural outcomes and allowing standardized placement of the artificial chords with a dedicated, reproducible technique.

The patient recovered very well from the intervention and is continuously doing well. A 30 day follow-up showed no complications.

„Using the ChordArt reduced the invasiveness and duration of the procedure by repairing the valve in a fast, precise and safe way. This allowed the Heart Team to focus on the procedure and timing rather than manually placing the artificial chords to resolve the mitral insufficiency“ said Dr. Alberto Weber, Her-zzentrum Hirslanden, Zurich, Switzerland, who proctored the procedure. „Thanks to the ease of the ChordArt deployment technique, this was the fastest mitral valve chordal repair I have ever witnessed.“

For Thomas Bauer, CEO of CoreMedic, „The first clinical use of ChordArt is a major milestone in our path towards developing the best in class transfemoral mitral valve chordal repair system“. Hubertus Leonhardt, Managing Partner of medical device investor SHS, commented: „In 2017 we invested in CoreMedic to advance the development of ChordArt. We look forward to the results of clinical trials that will validate the applications of this breakthrough device.“

About Mitral Regurgitation:
Mitral valve regurgitation (MR) is a condition in which the mitral valve leaflets fail to close properly, allowing significant backflow of blood from the left ventricle into the left atrium during systole. Valve disease prevalence rises dramatically with age, reaching epidemic levels in the elderly.
MR is the most common valve pathology in the US. Over 7 million people suffer from the disease and each year 250,000 patients are diagnosed with MR. If untreated, MR can cause shortness of breath, decreased cardiac output, intolerance to physical exercise, congestive heart failure and death.
The standard-of-care in surgically treating degenerative MR involves replacing ruptured or elongated valve chordae with artificial implants to restore the function of the valve.
Implanting the standard artificial chordae requires complex and long procedural steps. This complexity is associated with risks including failure of the valve repair or the need to repeat the operation, the use of a cardiac bypass machine and stopping the heart.

About CoreMedic:
CoreMedic is dedicated to develop devices and therapies to dramatically improve the quality of life of patients with heart valve diseases, a primary challenge in global healthcare.
CoreMedic“s flagship product ChordArt is a transfemoral system for mitral valve chordal repair in the beating heart. ChordArt™ offers a first line therapy option for patients with mitral valve dysfunction and represents a less invasive procedure compared to the current surgical methods with open-chest or trans-apical access. ChordArt is designed to allow mitral repair in a wider patient population. ChordArt™ is currently under clinical evaluation in European clinics.
CoreMedic is a privately held medical device company headquartered in Radolfzell, Germany with a subsidiary in Biel/Bienne, Switzerland. CoreMedic is EN ISO 13485 certified.
The investor base consists of founders, private investors and medical device investor SHS Gesellschaft für Beteiligungsmanagement mbH ( www.shs-capital.eu).
For further information, please visit www.coremedic.ch

Company-Contact
CoreMedic GmbH
Thomas Bauer
Bismarckstrasse 12
72072 Tübingen
Phone: 089 20003038
E-Mail: info@coremedic.ch
Url: http://www.coremedic.ch

Press
IWK GmbH
Dr. Reinhard Saller
Ohmstr. 1
80802 München
Phone: 089 20003038
E-Mail: reinhard.saller@iwk-cp.com
Url: http://www.iwk-cp.com

Medicine Wellness Health

Full speed ahead – New Celsius42

The relaunch of Celsius42 GmbH is just a few days away

Full speed ahead - New Celsius42

Eschweiler 01.05.2018 – after 4 months and many hours of work by our creative team, we look forward to publishing our new company website in the near future.

„This innovation represents a true milestone for the development of Celsius42,“ says Christian Hartmann, the company“s new CEO. „In addition to the remake of our corporate identity, there are many ongoing activities associated with our product range,“ he adds. „We are currently working on our vision up to the year 2025. Our company will present many innovations and product enhancements at the MEDICA tradeshow in Düsseldorf this year and over the course of the coming years.“

Parallel to product and market development, the company“s priorities for the coming months and years naturally also include global expansion. Moreover, technical and scientific cooperation will be at the core of this growth strategy.

We invite you to visit us at ESHO in Berlin from May 16-19 to learn more about our innovations in direct conversations. We look forward to your visit. Our communication channels will keep you updated about the further activities of our company.

Your Celsius42 Team

Who we are.

The people working at Celsius42 have one shared goal – to be united in the fight against cancer. To pool knowledge. To leverage partners and resources. To explore increasingly intelligent pathways in medical technology to finally win the fight. Medicine has fought this battle for a long time. A battle against a clever opponent: cancer. Hyperthermia is the active principle of Celsius42 products. Targeted
thermal energy that causes stress in cancer cells. It has many positive effects in chemotherapy or radiation therapy, but also strengthens the immune system.

The people at Celsius42 know that they are on
the right track. Their tenacity, energy and human experience make them a tight-knit team. With a single mission: to develop innovative hyperthermia products that help to fight cancer gently but effectively.

That is Celsius42. That is TCS – Tumor Cell Solution.

Contact
Celsius42 GmbH
Christian Hartmann
Hermann-Hollerith-Straße 11
52249 Eschweiler
Phone: +49 2403 7829 230
E-Mail: info@celsius42.de
Url: http://www.celsius42.de